ILOPROST

SynDRA canonical compound SYN0000449 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	PTGDR \| PTGER1 \| PTGER2 \| PTGER3 \| PTGER4 \| PTGFR \| PTGIR \| TBXA2R
Mechanism of action	platelet aggregation inhibitor \| prostanoid receptor agonist
Indication	pulmonary arterial hypertension (PAH)
Disease area	pulmonary

All known targets

ciloprost
endoprost
ilomedin
ventavis
ZK36374
ZK 36374
Aurlumyn
Ciloprost
Endoprost
Ilomedin
ZK-00036374
ZK-36374
Ventavis
Ilomedine
Iloprostum
Iloprostum [Latin]
E-1030
Iloprost (INN)
Iloprost [BAN:INN]
SH-401
Ventavis (TN)
ZK-363775
[3H]-Iloprost
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
JED5K35YGL
CHEBI:63916
DTXCID001333799
Iloprost Clathrate
RefChem:56820
B01AC11
5-cis Iloprost
SR-05000001498